Pharmaceutical firm Zydus Cadila received emergency use approval from the Drug Controller General of India (DCGI) - country's apex medicine regulator - on April 23 for the use of 'Virafin' in treating moderate COVID-19 cases.
Virafin, technically referred to as Pegylated Interferon alpha-2b, showed clinical and virological improvement in moderate COVID-19 cases, the company said.
Zydus has claimed that "91.15% of patients treated with PegIFN were RT-PCR negative by day 7", the report added.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.